

## The Synthesis of Daunosamine

By JOHN P. MARSH, JUN., CAROL W. MOSHER, EDWARD M. ACTON, and LEON GOODMAN\*

*(Life Sciences Research, Stanford Research Institute, Menlo Park, California 94025)*


DAUNOMYCIN<sup>1</sup> is a cytotoxic antibiotic whose antitumor activity has been studied.<sup>2</sup> The compound consists of an aglycone, daunomycinone,<sup>3a</sup> and a sugar, daunosamine.<sup>3b</sup> The sugar has been shown to be 3-amino-2,3,6-trideoxy-L-*lyxo*-hexose;

synthesis of a derivative of the D-enantiomer has been announced recently.<sup>4</sup> This Communication describes the synthesis of the natural L-sugar isolated as its hydrochloride (XI).

The conversion of L-rhamnose into L-rhamnol (I)

followed the literature procedure.<sup>5</sup> Methoxymercuration to (II), followed by reduction with potassium borohydride<sup>6</sup> furnished the 2,6-dideoxy-sugar (III) which is the enantiomer of methyl chromoside C.<sup>7</sup> The 3-*O*-monotoluene-*p*-sulphonate (VI), m.p. 86.5—86.9°,  $[\alpha]_D -116$  (CHCl<sub>3</sub>), was the principal product of the sulphonylation of (III), and could readily be separated by column chromatography as a crystalline solid from the minor amount of ditoluene-*p*-sulphonate that accompanied it. Reaction with methanolic sodium methoxide converted (VI) into the epoxide (V) which, without isolation, was opened with sodium azide to form mainly the 3-azido-sugar, the expected product based on conformational considerations. The

mild conditions with dilute sodium hydroxide in aqueous methanol to give the azido-alcohol (XII), an oil. Catalytic hydrogenation of (XII) afforded the crystalline glycoside (XIII), m.p. 109—110°,  $[\alpha]_D -210$  (CHCl<sub>3</sub>). Alternatively, (VIII) was hydrogenated to the aminosulphonate (IX) which gave a crystalline *N*-acetate (X), m.p. 140—141°,  $[\alpha]_D -135$  (CHCl<sub>3</sub>). Neighbouring-group displacement of the methanesulphonate in aqueous 2-methoxyethanol containing sodium acetate<sup>9</sup> yielded the *N*-acetate (XIV) and thence the crystalline *NO*-diacetate (XV), m.p. 187—188°,  $[\alpha]_D -204$  (CHCl<sub>3</sub>) which had a greater negative rotation than the derivative isolated from daunomycin<sup>3b</sup> but which agreed well in properties with



crude azide (IV) was converted into the crystalline methanesulphonate (VIII), m.p. 89—90°,  $[\alpha]_D -127$  (CHCl<sub>3</sub>). Two paths were available for the conversion of (VIII) into daunosamine hydrochloride (XI). In the preferred route the azidosulphonate (VIII) was treated with sodium benzoate in *NN*-dimethylformamide<sup>8</sup> yielding the benzoate (VII) as an analytically pure oil,  $[\alpha]_D -194$  (CHCl<sub>3</sub>) after chromatography, which was saponified under very

the synthetic derivative in the *D*-series.<sup>4</sup> Saponification of (XV) gave (XIII), identical with the material obtained in the first route.

The hydrolysis of (XIII) in 0.2*N*-hydrochloric acid at 90° for 90 min. gave, after careful work-up, the crystalline salt (XI), m.p. 160° (decomp.),  $[\alpha]_D^{26} -59.4 \rightarrow -54.2$ , which was identical chromatographically with an authentic sample.†

The authors thank the Cancer Chemotherapy

† We are indebted to Dr. F. Arcamone, Farmitalia S. A., Milan, Italy, for an authentic sample of daunosamine hydrochloride obtained from daunomycin. That sample had  $[\alpha]_D^{26} -76.2 \rightarrow -54.3$  (*c* 0.24 in H<sub>2</sub>O) and had m.p. 165° (decomp.). We attribute the small difference in melting-point behaviour to a difference in the anomeric composition of the two samples.

National Service Center, National Cancer Institute, National Institutes of Health, Public Health Service, for financial support, and Mr. O. P. Crews

and Mr. R. B. Bicknell for the large-scale preparation of some of the intermediates in this synthesis.

(Received, August 7th, 1967, Com. 838.)

<sup>1</sup> A. DiMarco, M. Gaetani, P. Orezzi, B. M. Scarpinato, R. Silvestrini, M. Soldati, T. Dasdia, and L. Valentini, *Nature*, 1964, **201**, 706.

<sup>2</sup> J. M. Vendetti, B. J. Abbott, A. DiMarco, and A. Goldin, *Cancer Chemotherapy Rep.*, 1966, **50**, 659.

<sup>3</sup> (a) F. Arcamone, G. Franceschi, P. Orezzi, G. Cassinelli, W. Barbieri, and R. Mondelli, *J. Amer. Chem. Soc.*, 1964, **86**, 5334; (b) F. Arcamone, G. Cassinelli, P. Orezzi, G. Franceschi, and R. Mondelli, *ibid.*, p. 5335.

<sup>4</sup> A. C. Richardson, *Chem. Comm.*, 1965, 627.

<sup>5</sup> B. Iselin and T. Reichstein, *Helv. Chim. Acta*, 1944, **27**, 1146.

<sup>6</sup> G. R. Inglis, J. C. P. Schwarz, and L. McLaren, *J. Chem. Soc.*, 1962, 1017.

<sup>7</sup> M. Miyamoto, Y. Kawamatsu, M. Shinohara, Y. Nakadaira, and K. Nakanishi, *Tetrahedron*, 1966, **22**, 2785.

<sup>8</sup> E. J. Reist, L. Goodman, R. R. Spencer, and B. R. Baker, *J. Amer. Chem. Soc.*, 1958, **80**, 3962.

<sup>9</sup> B. R. Baker and R. E. Schaub, *J. Org. Chem.*, 1954, **19**, 646.